Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALACE first-line advanced NSCLC ctDNA-adaptive cemiplimab study
2024-518812-38-00Phase 2Authorised
- Sponsor
- Fundación GECP
- Start
- Jul 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cemiplimab, carboplatin, pemetrexed and paclitaxel in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Fundación GECP. Primary endpoint: Overall survival at 24 months. Planned start Jul 2025; status: authorised.
02
Drugs
cemiplimabcarboplatinpemetrexedpaclitaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-518812-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518812-38-00.